These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 26947397

  • 21. The large-scale production of an artificial influenza virus-like particle vaccine in silkworm pupae.
    Nerome K, Sugita S, Kuroda K, Hirose T, Matsuda S, Majima K, Kawasaki K, Shibata T, Poetri ON, Soejoedono RD, Mayasari NL, Agungpriyono S, Nerome R.
    Vaccine; 2015 Jan 01; 33(1):117-25. PubMed ID: 25448101
    [Abstract] [Full Text] [Related]

  • 22. Baculovirus-produced influenza virus-like particles in mammalian cells protect mice from lethal influenza challenge.
    Tang XC, Lu HR, Ross TM.
    Viral Immunol; 2011 Aug 01; 24(4):311-9. PubMed ID: 21830902
    [Abstract] [Full Text] [Related]

  • 23. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.
    Smith GE, Flyer DC, Raghunandan R, Liu Y, Wei Z, Wu Y, Kpamegan E, Courbron D, Fries LF, Glenn GM.
    Vaccine; 2013 Sep 13; 31(40):4305-13. PubMed ID: 23891795
    [Abstract] [Full Text] [Related]

  • 24. Advances in influenza virus-like particles bioprocesses.
    Durous L, Rosa-Calatrava M, Petiot E.
    Expert Rev Vaccines; 2019 Dec 13; 18(12):1285-1300. PubMed ID: 31829068
    [Abstract] [Full Text] [Related]

  • 25. Chimeric virus-like particles for the delivery of an inserted conserved influenza A-specific CTL epitope.
    Cheong WS, Reiseger J, Turner SJ, Boyd R, Netter HJ.
    Antiviral Res; 2009 Feb 13; 81(2):113-22. PubMed ID: 19007818
    [Abstract] [Full Text] [Related]

  • 26. Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice.
    D'Aoust MA, Lavoie PO, Couture MM, Trépanier S, Guay JM, Dargis M, Mongrand S, Landry N, Ward BJ, Vézina LP.
    Plant Biotechnol J; 2008 Dec 13; 6(9):930-40. PubMed ID: 19076615
    [Abstract] [Full Text] [Related]

  • 27. Next generation vaccines and vectors: Designing downstream processes for recombinant protein-based virus-like particles.
    Effio CL, Hubbuch J.
    Biotechnol J; 2015 May 13; 10(5):715-27. PubMed ID: 25880158
    [Abstract] [Full Text] [Related]

  • 28. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
    Liu Y, Zhou J, Yu Z, Fang D, Fu C, Zhu X, He Z, Yan H, Jiang L.
    BMC Microbiol; 2014 Dec 18; 14():233. PubMed ID: 25520151
    [Abstract] [Full Text] [Related]

  • 29. Assembly and immunological properties of a bivalent virus-like particle (VLP) for avian influenza and Newcastle disease.
    Shen H, Xue C, Lv L, Wang W, Liu Q, Liu K, Chen X, Zheng J, Li X, Cao Y.
    Virus Res; 2013 Dec 26; 178(2):430-6. PubMed ID: 24050994
    [Abstract] [Full Text] [Related]

  • 30. H5N1 influenza virus-like particle vaccine protects mice from heterologous virus challenge better than whole inactivated virus.
    Ren Z, Ji X, Meng L, Wei Y, Wang T, Feng N, Zheng X, Wang H, Li N, Gao X, Jin H, Zhao Y, Yang S, Qin C, Gao Y, Xia X.
    Virus Res; 2015 Mar 16; 200():9-18. PubMed ID: 25599603
    [Abstract] [Full Text] [Related]

  • 31. Integrated molecular and bioprocess engineering for bacterially produced immunogenic modular virus-like particle vaccine displaying 18 kDa rotavirus antigen.
    Tekewe A, Fan Y, Tan E, Middelberg AP, Lua LH.
    Biotechnol Bioeng; 2017 Feb 16; 114(2):397-406. PubMed ID: 27497268
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. A conserved matrix epitope based DNA vaccine protects mice against influenza A virus challenge.
    Kumar P, Khanna M, Kumar B, Rajput R, Banerjea AC.
    Antiviral Res; 2012 Jan 16; 93(1):78-85. PubMed ID: 22086129
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Production and characterization of mammalian virus-like particles from modified vaccinia virus Ankara vectors expressing influenza H5N1 hemagglutinin and neuraminidase.
    Schmeisser F, Adamo JE, Blumberg B, Friedman R, Muller J, Soto J, Weir JP.
    Vaccine; 2012 May 14; 30(23):3413-22. PubMed ID: 22465746
    [Abstract] [Full Text] [Related]

  • 38. Protective efficacy of a bacterially produced modular capsomere presenting M2e from influenza: extending the potential of broadly cross-protecting epitopes.
    Wibowo N, Hughes FK, Fairmaid EJ, Lua LH, Brown LE, Middelberg AP.
    Vaccine; 2014 Jun 17; 32(29):3651-5. PubMed ID: 24795225
    [Abstract] [Full Text] [Related]

  • 39. Critical assessment of influenza VLP production in Sf9 and HEK293 expression systems.
    Thompson CM, Petiot E, Mullick A, Aucoin MG, Henry O, Kamen AA.
    BMC Biotechnol; 2015 May 16; 15():31. PubMed ID: 25981500
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.